Eli Lilly announced on June 8 that its triple-G therapy retatrutide demonstrated significant weight reduction in patients with obesity, reinforcing the company's lead in the metabolic therapy sector. The announcement was made during the 2026 annual congress of the American Diabetes Association.
The company is evaluating three doses of retatrutide—4 mg, 9 mg, and 12 mg—in its Phase 3 TRIUMPH-1 study. Recent data from an 80-week analysis showed a 28.3% reduction in weight for patients receiving the highest dose without placebo adjustment. At the ADA meeting, Lilly presented updated results extending to 104 weeks, indicating a 30.3% decrease in body weight among participants with a body mass index of at least 35 kg/m2.
BMO Capital Markets analysts said these findings suggest that retatrutide “sets [a] new standard in weight loss.” In their June 7 note to investors, they wrote, “Extension data from TRIUMPH-1 shows further weight loss in overweight/obese patients, strengthening retatrutide’s profile in the indication.” William Blair analysts described the drug as breaking “new record[s] in ‘Weight Loss Olympics’” and noted that Lilly had positioned it within an ultra-high potency category within its product portfolio.
In addition to weight loss benefits, Lilly reported that patients treated with retatrutide experienced a 73.1% improvement in knee osteoarthritis pain scores and a 60.6% decrease in apnea or hypopnea episodes per hour compared to baseline measurements. BMO Capital Markets analysts said these additional benefits “likely exceed investor expectations” and provide “further support for broader benefits of retatrutide’s robust weight loss in secondary conditions.”
Lilly began its Phase 3 TRIUMPH program for retatrutide in 2023 to evaluate effects not only on obesity but also obstructive sleep apnea and knee osteoarthritis. More than 5,800 patients have enrolled across four studies under this program so far, with additional data expected over the next year, according to company statements released Saturday.
At the same conference, Lilly presented results for its oral GLP-1 therapy Foundayo, highlighting it as suitable for menopausal women without food or water restrictions. A posthoc analysis from ATTAIN-1 found more than a 14% reduction in body weight among peri- and post-menopausal women using Foundayo; similar outcomes were observed across all menopause stages—including those with type 2 diabetes—in ATTAIN-2.
